Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma

作者：Zhongqing Liang, Ruolan Sun, Pengcheng Tu, Yan Liang, Liang Li, Fuyan Liu, Yong Bian, Gang Yin, Fan Zhao, Mingchen Jiang, Junfei Gu, Decai Tang · 发表于：Frontiers in Immunology · 年份：2022 · DOI：10.3389/fimmu.2022.944286 · 被引用次数：16 · 研究领域：Cancer Immunotherapy and Biomarkers、Ferroptosis and cancer prognosis、Genetic factors in colorectal cancer

Introduction: Colorectal cancer shows high incidence and mortality rates. Immune checkpoint blockade can be used to treat colorectal carcinoma (CRC); however, it shows limited effectiveness in most patients. Methods: To identify patients who may benefit from immunotherapy using immune checkpoint inhibitors, we constructed an immune-related gene prognostic index (IRGPI) for predicting the efficacy of immunotherapy in patients with CRC. Transcriptome datasets and clinical information of patients with CRC were used to identify differential immune-related genes between tumor and para-carcinoma tissue. Using weighted correlation network analysis and Cox regression analysis, the IRGPI was constructed, and Kaplan-Meier analysis was used to evaluate its predictive ability. We also analyzed the molecular and immune characteristics between IRGPI high-and low-risk subgroups, performed sensitivity analysis of ICI treatment, and constructed overall survival-related receiver operating characteristic curves to validate the IRGPI. Finally, IRGPI genes and tumor immune cell infiltration in CRC model mice with orthotopic metastases were analyzed to verify the results. Results: The IRGPI was constructed based on the following 11 hub genes: ADIPOQ, CD36, CCL24, INHBE, UCN, IL1RL2, TRIM58, RBCK1, MC1R, PPARGC1A, and LGALS2. Patients with CRC in the high-risk subgroup showed longer overall survival than those in the low-risk subgroup, which was confirmed by GEO database. Clinicopathological featur...